Biodesix expects $101M-$103M 2026 revenue and about 115 sales reps by year-end
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Biodesix (BDSX) Q3 2026 MANAGEMENT VIEW * "Biodesix continued to make meaningful progress in the third quarter with total revenue growing 10%, diagnostic testing revenue increasing 16%, test volumes growing 24% and gross margin remaining strong at 81%."…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishResults missed management expectations, with third-quarter revenue up 10%.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01CEO Scott Hutton said results did not meet expectations.
- 02Total revenue grew 10% and diagnostic testing revenue rose 16%.
- 03The shortfall was attributed to fewer sales reps than planned and greater seasonality.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets